What's in Innovent Biologics (Suzhou) Co. Ltd.'s pipeline?

Innovent Biologics (Suzhou) Co. Ltd. has 73 drugs in our index: 3 marketed, 0 filed, 16 in Phase 3, 8 in Phase 2, 46 in Phase 1.

Which companies overlap with Innovent Biologics (Suzhou) Co. Ltd.'s portfolio?

Top competitors by shared drug class: Bio-Thera Solutions, Sun Yat-sen University, Shanghai Hengrui Pharmaceutical Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Celltrion.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/innovent-biologics-suzhou-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Innovent Biologics (Suzhou) Co. Ltd. — Portfolio Competitive Intelligence Brief

Innovent Biologics (Suzhou) Co. Ltd. pipeline: 3 marketed, 0 filed, 16 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 16 Phase 3 8 Phase 2 46 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Intensive treatment	Intensive treatment	marketed
regular treatment	regular treatment	marketed
Teprotumumab N01	Teprotumumab N01	marketed	IGF-1 receptor antagonist monoclonal antibody	IGF-1R (Insulin-like Growth Factor-1 Receptor)	Immunology / Ophthalmology
IBI363	IBI363	phase 3	Bispecific checkpoint inhibitor	PD-1 and TIM-3	Oncology
paclitaxel/Gemcitabine/Liposomal doxorubicin	paclitaxel/Gemcitabine/Liposomal doxorubicin	phase 3	Taxane, Nucleoside analog, Anthracycline antibiotic		Oncology
IBI308	IBI308	phase 3	PD-1 inhibitor	PD-1	Oncology
IBI354	IBI354	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β	Oncology
IBI310	IBI310	phase 3	Bispecific checkpoint inhibitor	PD-1 and TIM-3	Oncology
IBI310&Sintilimab	IBI310&Sintilimab	phase 3	Bispecific antibody (IBI310) + PD-1 inhibitor (Sintilimab)	CTLA-4, TIM-3 (IBI310); PD-1 (Sintilimab)	Oncology
IBI343	IBI343	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β	Oncology
dose 1 IBI302	dose 1 IBI302	phase 3	PD-1 inhibitor	PD-1	Oncology
IBI306	IBI306	phase 3	PD-1 inhibitor	PD-1	Oncology

Therapeutic area mix

Oncology · 16
Immunology / Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bio-Thera Solutions · 3 shared drug classes
Sun Yat-sen University · 3 shared drug classes
Shanghai Hengrui Pharmaceutical Co., Ltd. · 3 shared drug classes
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
Celltrion · 2 shared drug classes
Akeso · 2 shared drug classes
Beijing Suncadia Pharmaceuticals Co., Ltd · 2 shared drug classes
3D Medicines (Sichuan) Co., Ltd. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Innovent Biologics (Suzhou) Co. Ltd.:

Cite this brief

Drug Landscape (2026). Innovent Biologics (Suzhou) Co. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/innovent-biologics-suzhou-co-ltd. Accessed 2026-05-16.